Adherence to combination therapy: influence on sustained virologic response and economic impact

This publication has 29 references indexed in Scilit:

• Current therapy for hepatitis C: pegylated interferon and ribavirin
  Clinics in Liver Disease, 2003
• The burden of hepatitis C in the United States
  Hepatology, 2002
• Side effects of therapy of hepatitis C and their management
  Hepatology, 2002
• Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
  Gastroenterology, 2002
• Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
  New England Journal of Medicine, 2002
• Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose
  Journal of Hepatology, 2002
• Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
  Published by Elsevier ,2001
• Estimating future hepatitis C morbidity, mortality, and costs in the United States
  American Journal of Public Health, 2000
• The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States
  Hepatology, 2000
• Epidemiology of hepatitis C in the United States
  The American Journal of Medicine, 1999